Results 31 to 40 of about 822 (144)

Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience

Case Reports in Medicine, 2020
Background. Diabetes and other metabolic abnormalities including high triglycerides (TGs) are commonly seen comorbid conditions in patients having nonalcoholic fatty liver disease (NAFLD).
Sayak Roy
doaj   +1 more source

A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy. [PDF]

PLoS ONE, 2016
OBJECTIVE:This study was designed to explore the efficacy and safety of saroglitazar 4 mg on hypertriglyceridemia in patients with HIV associated lipodystrophy.
Alka Deshpande, Harsh Toshniwal, Shashank Joshi, Rajendrakumar H Jani   +3 more
doaj   +1 more source

Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study

National Journal of Physiology, Pharmacy and Pharmacology, 2021
Background: Diabetes mellitus when associated with dyslipidemia poses a different direction of management. For this subgroup of patients, we need stricter and different approach to improve treatment outcome and overall benefit.
Vidhya Sreekumar, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, Jyotirmoyee Jena   +5 more
doaj   +1 more source

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

Biomolecules, 2023
The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the increasing medical and economic burden incurred for their treatment.
Shotaro Kamata, Akihiro Honda, Isao Ishii   +2 more
doaj   +1 more source

Saroglitazar suppresses KIM-1 and type IV collagen in high fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Nephropathy is the most common comorbidity linked to T2D. The present study aimed to examine the potential of saroglitazar in the context of a high-fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.
Rizwan Ahamad, Uma Bhandari, Sayima Nabi, Shweta Sharma   +3 more
doaj   +1 more source

The First Approved Agent in the Glitazar’s Class: Saroglitazar

Current Drug Targets, 2014
The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been
Beda Durga Prasad, A. Srinivas Rao, Mondra Sreekanth, Sheelam Sumathi, Sreenivas Pasula, Vadlamudi Naga Ratna Sai   +5 more
openaire   +4 more sources

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Cardiovascular Diabetology, 2020
Background The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention.
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, for the PRESS XII study group, Deven Parmar   +9 more
doaj   +1 more source

Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Non-alcoholic fatty liver disease (NAFLD) is a chronic steatohepatitis disorder. If left untreated, it can progress to hepatocellular carcinoma.
Reza Afarin, Negar Dinarvand, Hossein Azizi Dariuni, Ghazal Orak, Bahar Jaberian Asl, Reza Azizi, Azam Khedri   +6 more
doaj   +1 more source

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Cardiovascular Diabetology, 2019
Background Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively.
Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil, Ashok Jaiswal   +6 more
doaj   +1 more source

Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia - A Review [PDF]

Journal of Young Pharmacists, 2014
Diabetes mellitus is a worldwide prevalent chronic disease with a significant disease burden. The associated dyslipidemia adds to the lethality of type 2 diabetes mellitus and requires newer and better treatment strategies. Peroxisome proliferator activated receptor (PPAR) α and γ agonists are approved hypolipidemic and anti-diabetic agents ...
Arun Sharma, Amarnath S, Devendra Singh Kushwah, Ramaswamy S   +3 more
openaire   +1 more source